
Peter Bach has another crazy idea.
Bach, the director for the center for health policy and outcomes at Memorial Sloan Kettering Cancer Center, thinks that biosimilars, the would-be cheaper alternatives to the biologic drugs that are among the industry’s most expensive, are a lost cause.
A balanced, interesting and wonderful article.